Phase 2 trial of RGX-314 to treat wet AMD underway

The first patient has been dosed in a phase 2 trial evaluating suprachoroidal delivery of RGX-314 to treat wet age-related macular degeneration, according to a Regenxbio press release.
AAVIATE is a multicenter, open-label, randomized, active-controlled, dose-escalation trial evaluating the efficacy, safety and tolerability of suprachoroidal delivery of RGX-314 using the SCS microinjector. About 40 patients with severe wet AMD will be randomly assigned 3:1 to receive RGX-314 vs. monthly 0.5 mg ranibizumab intravitreal injections, with two dose levels of RGX-314 evaluated, 2.5 × 1011 GC per eye

Full Story →